NO942155L - - Google Patents
Info
- Publication number
- NO942155L NO942155L NO942155A NO942155A NO942155L NO 942155 L NO942155 L NO 942155L NO 942155 A NO942155 A NO 942155A NO 942155 A NO942155 A NO 942155A NO 942155 L NO942155 L NO 942155L
- Authority
- NO
- Norway
- Prior art keywords
- pct
- toremifene
- desmethyltamoxifen
- tamoxifen
- sec
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nanotechnology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB919126209A GB9126209D0 (en) | 1991-12-10 | 1991-12-10 | Drug formulations for parenteral use |
| PCT/FI1992/000339 WO1993011757A1 (en) | 1991-12-10 | 1992-12-10 | Drug formulations for parenteral use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO942155D0 NO942155D0 (no) | 1994-06-09 |
| NO942155L true NO942155L (cs) | 1994-06-10 |
| NO308578B1 NO308578B1 (no) | 2000-10-02 |
Family
ID=10706001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO942155A NO308578B1 (no) | 1991-12-10 | 1994-06-09 | Parenteralt legemiddelpreparat |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5571534A (cs) |
| EP (1) | EP0616529B1 (cs) |
| JP (1) | JP3558344B2 (cs) |
| AT (1) | ATE149828T1 (cs) |
| AU (1) | AU667861B2 (cs) |
| CA (1) | CA2125408C (cs) |
| DE (1) | DE69218241T2 (cs) |
| FI (1) | FI942728A7 (cs) |
| GB (1) | GB9126209D0 (cs) |
| NO (1) | NO308578B1 (cs) |
| WO (1) | WO1993011757A1 (cs) |
| ZA (1) | ZA929592B (cs) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6395494B1 (en) | 1993-05-13 | 2002-05-28 | Neorx Corporation | Method to determine TGF-β |
| DK0695169T3 (da) * | 1993-04-22 | 2003-03-17 | Skyepharma Inc | Multivesikulære liposomer med indkapslet cyclodextrin og farmakologisk aktive forbindelser samt fremgangsmåder til anvendelse af disse |
| WO1995015746A1 (en) * | 1993-12-10 | 1995-06-15 | The School Of Pharmacy | Liposome delivery systems |
| GB9411115D0 (en) * | 1994-06-03 | 1994-07-27 | Secr Defence | Stabilisation of photosensitive material |
| GB9609171D0 (en) * | 1996-05-02 | 1996-07-03 | Orion Yhtymae Oy | Antioxidant compounds |
| AU6959898A (en) | 1997-04-11 | 1998-11-11 | David J. Grainger | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies |
| DE69804169T2 (de) * | 1997-06-27 | 2002-08-29 | Akzo Nobel N.V., Arnheim/Arnhem | Oral anzuwendende flüssige Arzneilösung |
| US6077871A (en) * | 1997-11-26 | 2000-06-20 | Pfizer Inc. | Droloxifene pharmaceutical compositions |
| US6410043B1 (en) | 1998-05-07 | 2002-06-25 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
| US6413533B1 (en) * | 1998-05-07 | 2002-07-02 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
| US20040176470A1 (en) * | 1998-05-07 | 2004-09-09 | Steiner Mitchell S. | Method for treatment and chemoprevention of prostate cancer |
| US20040092602A1 (en) * | 1998-05-07 | 2004-05-13 | Steiner Mitchell S. | Method for treatment and chemoprevention of prostate cancer |
| US6632447B1 (en) * | 1998-05-07 | 2003-10-14 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
| US20030130316A1 (en) * | 2000-03-20 | 2003-07-10 | Steiner Mitchell S. | Method for chemoprevention of prostate cancer |
| EA003466B1 (ru) * | 1998-05-07 | 2003-06-26 | Те Юниверсити Оф Теннесси Рисерч Корпорейшн | Способ химиопрофилактики рака предстательной железы |
| PT1135193E (pt) * | 1998-12-04 | 2003-01-31 | Max Delbrueck Centrum | Agentes para o tratamento de tumores a base de lipossomas e compreendendo tamoxifeno |
| FI109332B (fi) | 1998-12-17 | 2002-07-15 | Orion Yhtymae Oyj | Toremifeenin liukoisia koostumuksia |
| FI982733L (fi) | 1998-12-17 | 2000-06-18 | Orion Yhtymae Oyj | Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia |
| US6303157B1 (en) | 2000-05-31 | 2001-10-16 | Kava Pharmaceuticals, Inc. | Extracts of kava-kava |
| US20040029831A1 (en) * | 2000-05-31 | 2004-02-12 | Kava Pharmaceuticals, Inc. | Extracts of kava-kava |
| US6613083B2 (en) | 2001-05-02 | 2003-09-02 | Eckhard Alt | Stent device and method |
| US20080249183A1 (en) * | 2001-11-29 | 2008-10-09 | Steiner Mitchell S | Treatment of androgen-deprivation induced osteoporosis |
| MXPA04005112A (es) | 2001-11-29 | 2005-04-29 | Gtx Inc | Prevencion y tratamiento de osteoporosis inducida por privacion de androgeno. |
| US20050239747A1 (en) * | 2004-04-21 | 2005-10-27 | Pharmaceutical Industry Technology And Development Center | Compositions and methods of enhanced transdermal delivery of steroid compounds and preparation methods |
| WO2006001035A2 (en) * | 2004-06-28 | 2006-01-05 | Lifecare Innovations Pvt. Ltd. | Synergistic liposomal tamoxifen composition for topical application and method of preparing thereof. |
| US20060019989A1 (en) * | 2004-07-21 | 2006-01-26 | Steiner Mitchell S | Compositions comprising 5-alpha reductase inhibitors and SERMs and methods of use thereof |
| US20160106717A1 (en) | 2004-09-24 | 2016-04-21 | Gen Pharma Holdings LLC | Cai-based systems and methods for the localized treatment of uveitis |
| ES2369554T3 (es) | 2004-09-24 | 2011-12-01 | Rfe Pharma Llc | Carboxi-amido-triazoles para el tratamiento local de enfermedades oculares. |
| WO2006052922A2 (en) * | 2004-11-08 | 2006-05-18 | Eastman Chemical Company | Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds |
| US20060105045A1 (en) * | 2004-11-08 | 2006-05-18 | Buchanan Charles M | Cyclodextrin solubilizers for liquid and semi-solid formulations |
| US8101745B2 (en) * | 2004-12-16 | 2012-01-24 | The Regents Of The University Of California | Lung-targeted drugs |
| US20060270641A1 (en) * | 2005-05-31 | 2006-11-30 | Steiner Mitchell S | Method for chemoprevention of prostate cancer |
| TW200726485A (en) * | 2005-07-01 | 2007-07-16 | Alza Corp | Liposomal delivery vehicle for hydrophobic drugs |
| US8998881B2 (en) | 2005-08-10 | 2015-04-07 | Alza Corporation | Method for delivering drugs to tissue under microjet propulsion |
| WO2007078060A1 (en) * | 2005-12-30 | 2007-07-12 | Amorepacific Corporation | Polymer-liposome nano-complexes and the preparation method thereof, and the composition of skin external application containing the same |
| ES2402907T3 (es) | 2006-10-19 | 2013-05-10 | Genzyme Corporation | Roscovitina para el tratamiento de ciertas enfermedades quísticas |
| JP5622719B2 (ja) * | 2009-03-30 | 2014-11-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | リポソーム組成物の製造方法 |
| PE20120923A1 (es) | 2009-03-30 | 2012-08-27 | Eisai Randd Man Co Ltd | Composiciones farmaceuticas comprendiendo liposomas que contiene eribulina o una sal del mismo |
| JP2013537219A (ja) | 2010-09-16 | 2013-09-30 | シモダ・バイオテック・(ピーティーワイ)・リミテッド | フルベストラント組成物および使用方法 |
| WO2013008083A1 (en) | 2011-07-13 | 2013-01-17 | National Institute Of Pharmaceutical Education And Research (Niper) | Pharmaceutical composition for enhancing anticancer efficacy of tamoxifen |
| JP2014526512A (ja) | 2011-09-18 | 2014-10-06 | ユーロ−セルティーク エス.エイ. | 医薬組成物 |
| TWI573792B (zh) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | 新穎治療劑 |
| BR112015023705A8 (pt) | 2013-03-15 | 2020-03-17 | Univ California | compostos, composições farmacêuticas, usos de um composto, e método para síntese do composto da fórmula (ia) |
| GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| BR112017005111B1 (pt) | 2014-09-15 | 2023-02-14 | The Regents Of The University Of California | Compostos análogos de nucleotídeo acíclico, composição farmacêutica contendo tais compostos, e usos da composição no tratamento de uma infecção por papilomavírus |
| CN105748442B (zh) * | 2016-04-07 | 2019-04-12 | 天津中医药大学 | 一种红景天苷及他莫昔芬的双载药抗乳腺癌纳米制剂的制备方法 |
| ES2952680T3 (es) | 2016-04-28 | 2023-11-03 | Eisai R&D Man Co Ltd | Eribulina para inhibir el crecimiento tumoral |
| CN109562102A (zh) | 2016-06-17 | 2019-04-02 | 宾夕法尼亚大学董事会 | 用于预防和/或治疗癌症的化合物、组合物和方法 |
| WO2018068832A1 (en) | 2016-10-11 | 2018-04-19 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
| GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
| GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
| GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
| GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
| AU2018294327A1 (en) * | 2017-06-30 | 2020-01-23 | Celgene Corporation | Compositions and methods of use of 2-(4-chlorophenyl)-N-((2-(2,6-doxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide |
| WO2019118855A1 (en) * | 2017-12-14 | 2019-06-20 | The Trustees Of The University Of Pennsylvania | Compounds and compositions for prevention and/or treatment of cancer |
| CA3124001A1 (en) | 2018-12-18 | 2020-06-25 | Mundipharma International Corporation Limited | Compounds for treating lymphoma or a t-cell malignant disease |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| WO2024231293A1 (en) | 2023-05-05 | 2024-11-14 | Euro-Celtique S.A. | Combinations for treating cancer |
| CN117224487B (zh) * | 2023-10-07 | 2025-08-08 | 山东新时代药业有限公司 | 一种枸橼酸托瑞米芬脂质体、制备方法及制剂 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5793909A (en) * | 1980-12-03 | 1982-06-11 | Sankyo Co Ltd | Carcinostatic pharmaceutical having directivity to specific internal organ and its preparation |
| FR2502951B1 (fr) * | 1981-04-06 | 1985-12-06 | Sandoz Sa | Compositions pharmaceutiques topiques sous forme d'une micro-emulsion |
| FI67538C (fi) * | 1982-05-27 | 1985-04-10 | Farmos Oy | Foerfarande foer framstaellning av (z)-1,2-difenyl-1-(4-(2-(n n-dimetylamino)etoxi)fenyl)-1-buten |
| DE3331459A1 (de) * | 1982-08-31 | 1984-03-01 | Martin Dr.med. 6900 Heidelberg Berger | Zubereitung zur tumorbehandlung mit einem gehalt an diazoxid und dessen verwendung |
| EP0152379A3 (de) * | 1984-02-15 | 1986-10-29 | Ciba-Geigy Ag | Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen |
| JPS60208910A (ja) * | 1984-03-31 | 1985-10-21 | Green Cross Corp:The | 水難溶性薬物・リン脂質複合体の製造方法 |
| GB8604528D0 (en) * | 1986-02-24 | 1986-04-03 | Ici Plc | Therapeutic agents |
| IE62095B1 (en) * | 1988-03-29 | 1994-12-14 | Univ Florida | Pharmaceutical formulations for parenteral use |
| JP2847783B2 (ja) * | 1988-08-11 | 1999-01-20 | 日清製粉株式会社 | 抗癌活性増強剤 |
| DE3827974A1 (de) * | 1988-08-18 | 1990-02-22 | Boehringer Mannheim Gmbh | Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen |
| MY106598A (en) * | 1988-08-31 | 1995-06-30 | Australian Commercial Res & Development Ltd | Compositions and methods for drug delivery and chromatography. |
| DE3837596A1 (de) * | 1988-11-05 | 1990-05-10 | Rosink Gmbh & Co Kg | Kannenstock |
| FR2640137A1 (fr) * | 1988-12-08 | 1990-06-15 | Texinfine Sa | Systemes transporteurs de principes actifs lipophiles et leur procede d'obtention |
| AU7963691A (en) * | 1990-05-17 | 1991-12-10 | Baylor College Of Medicine | Growth inhibitors and methods of treating cancer and cell proliferative diseases |
-
1991
- 1991-12-10 GB GB919126209A patent/GB9126209D0/en active Pending
-
1992
- 1992-12-10 AU AU31599/93A patent/AU667861B2/en not_active Ceased
- 1992-12-10 US US08/244,549 patent/US5571534A/en not_active Expired - Lifetime
- 1992-12-10 FI FI942728A patent/FI942728A7/fi not_active IP Right Cessation
- 1992-12-10 ZA ZA929592A patent/ZA929592B/xx unknown
- 1992-12-10 DE DE69218241T patent/DE69218241T2/de not_active Expired - Fee Related
- 1992-12-10 EP EP93900114A patent/EP0616529B1/en not_active Expired - Lifetime
- 1992-12-10 AT AT93900114T patent/ATE149828T1/de not_active IP Right Cessation
- 1992-12-10 CA CA002125408A patent/CA2125408C/en not_active Expired - Lifetime
- 1992-12-10 WO PCT/FI1992/000339 patent/WO1993011757A1/en not_active Ceased
- 1992-12-10 JP JP51065093A patent/JP3558344B2/ja not_active Expired - Lifetime
-
1994
- 1994-06-09 NO NO942155A patent/NO308578B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB9126209D0 (en) | 1992-02-12 |
| NO308578B1 (no) | 2000-10-02 |
| JP3558344B2 (ja) | 2004-08-25 |
| EP0616529B1 (en) | 1997-03-12 |
| DE69218241T2 (de) | 1997-06-19 |
| FI942728L (fi) | 1994-06-10 |
| FI942728A0 (fi) | 1994-06-10 |
| ATE149828T1 (de) | 1997-03-15 |
| FI942728A7 (fi) | 1994-06-10 |
| AU3159993A (en) | 1993-07-19 |
| CA2125408A1 (en) | 1993-06-23 |
| WO1993011757A1 (en) | 1993-06-24 |
| NO942155D0 (no) | 1994-06-09 |
| US5571534A (en) | 1996-11-05 |
| EP0616529A1 (en) | 1994-09-28 |
| JPH07501813A (ja) | 1995-02-23 |
| CA2125408C (en) | 2004-04-20 |
| AU667861B2 (en) | 1996-04-18 |
| ZA929592B (en) | 1993-08-06 |
| DE69218241D1 (de) | 1997-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO942155L (cs) | ||
| KR910011896A (ko) | 신규한 글리코펩티드 유도체 | |
| NO954320L (no) | Lyosfærer omfattende gonadotropin | |
| ES2115945T3 (es) | Preparaciones topicas cosmeticas y medicinales. | |
| CA2033725A1 (en) | Pharmaceutical and cosmetic compositions containing a salt of cholanic acid | |
| NO952321D0 (no) | Polypeptid, samt anti-HIV-preparat fremstilt fra dette | |
| ES2097546T3 (es) | Preparaciones cosmeticas desodorantes que contienen esteres di- o trigliceridos. | |
| EP1238677A3 (en) | Parenteral fat emulsions comprising edetate as preservative | |
| MY114300A (en) | Pesticidal mixtures comprising diafenthiuron and a carbamate | |
| AU4415293A (en) | Peptide dispersion as carrier for sparingly water soluble active ingredients | |
| EP0158481A3 (en) | Hair care compositions | |
| KR960000247A (ko) | 사이클로스포린a 함유 조성물 및 그의 제조방법 | |
| MXPA97007996A (es) | Preparado para el transporte de sustancias activas a traves de barreras. | |
| KR900003163A (ko) | 시클로헥산 유도체 | |
| KR900014406A (ko) | 세펨 화합물 및 이의 제조방법 | |
| CA2378425A1 (en) | Aqueous pharmaceutical formulation of moxifloxacin or salts thereof | |
| EP0327709A3 (en) | Novel platinum complex, antineoplastic agent containing the same, intermediate therefor, preparation method and use | |
| KR900001715A (ko) | Bu-3608 유도체 | |
| FI75991B (fi) | Foerfarande foer framstaellning av stabil isotonisk vaetskekomposition, vilken kan anvaendas som oegonmedicinpreparat. | |
| BR9509634A (pt) | Solução aquosa concentrada estável ao armazenamento para infusao uso da mesma e processos de preparação da mesma de tratamento de um paciente necessitando de um inibidor de trombina e de estabilização de um inibidor de trombina ativo | |
| KR890008136A (ko) | 항균성 9-데옥소-9a-알릴 및 프로파길-9a-아자-9a-호모에리트로 마이신 A 유도체 | |
| SE9103110D0 (sv) | New drug formulation | |
| CA2456970A1 (en) | Drug formulations for parenteral use | |
| KR980002033A (ko) | 트리아졸 유도체 또는 그 염 | |
| KR900701262A (ko) | 췌장염 등에 대한 치료제 |